Relay Therapeutics (RLAY) Change in Acquisitions & Divestments (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $83.8 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $83.8 million, up 29.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $335.2 million (down 29.18% YoY), and the FY2025 annual result was $316.2 million, down 48.3% from the prior year.
• Change in Acquisitions & Divestments rose to $83.8 million in Q1 2026 per RLAY's latest filing, from $69.5 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $203.1 million in Q1 2024 and troughed at $18.1 million in Q1 2022.
• A 5-year average of $118.5 million and a median of $104.1 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments sank 95.31% in 2022, then soared 867.09% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $183.0 million in 2022, then rose by 7.43% to $196.6 million in 2023, then tumbled by 47.07% to $104.1 million in 2024, then slumped by 33.26% to $69.5 million in 2025, then gained by 20.64% to $83.8 million in 2026.
• Business Quant data shows RLAY's Change in Acquisitions & Divestments at $83.8 million in Q1 2026, $69.5 million in Q4 2025, and $97.8 million in Q3 2025.